Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $45

Benzinga · 07/08 16:02
Citigroup analyst Patrick Donnelly maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $24 to $45.